US Patent 7591994 Camptothecin-binding moiety conjugates
Patent 7591994 was granted and assigned to IMMUNOMEDICS, INC. on September, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+319 characters)
Article
Patent abstract
The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07591994 Camptothecin-binding moiety conjugates US Patent 7591994 Camptothecin-binding moiety conjugates
Infobox
Patent Number
0759199400
Patent Number
759199400
Edits on 1 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075919940
Date of Patent
September 22, 2009
0Patent Application Number
120268110
Date Filed
February 6, 2008
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075919940
Date of Patent
September 22, 2009
0Patent Application Number
120268110
Date Filed
February 6, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07591994 Camptothecin-binding moiety conjugates
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07591994
Date of patent
September 22, 2009
Patent application number
12026811
Date Filed
February 6, 2008
Patent primary examiner
Find more entities like US Patent 7591994 Camptothecin-binding moiety conjugates
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
